DBV Technologies (DBVT) Competitors

DBV Technologies (NASDAQ:DBVT) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.

Does the MarketBeat Community prefer DBVT or ABCL?

DBV Technologies received 350 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 75.68% of users gave AbCellera Biologics an outperform vote while only 54.13% of users gave DBV Technologies an outperform vote.

Company	Underperform	Outperform
DBV Technologies	Outperform Votes 406 54.13%	Underperform Votes 344 45.87%
AbCellera Biologics	Outperform Votes 56 75.68%	Underperform Votes 18 24.32%

Does the media favor DBVT or ABCL?

In the previous week, DBV Technologies had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for DBV Technologies and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.97 beat DBV Technologies' score of 0.74 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer DBVT or ABCL?

DBV Technologies presently has a consensus target price of $25.00, indicating a potential upside of 190.36%. AbCellera Biologics has a consensus target price of $7.50, indicating a potential upside of 201.20%. Given AbCellera Biologics' higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
AbCellera Biologics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has preferable valuation and earnings, DBVT or ABCL?

DBV Technologies has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$15.73M	14.99	-$72.73M	-$5.00	-1.72
AbCellera Biologics	$28.83M	25.73	-$146.40M	-$0.55	-4.53

Which has more volatility and risk, DBVT or ABCL?

DBV Technologies has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Do institutionals and insiders believe in DBVT or ABCL?

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by insiders. Comparatively, 28.0% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is DBVT or ABCL more profitable?

AbCellera Biologics has a net margin of -533.32% compared to DBV Technologies' net margin of -815.73%. AbCellera Biologics' return on equity of -15.73% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-815.73%	-106.07%	-76.17%
AbCellera Biologics	-533.32%	-15.73%	-12.22%

Summary

AbCellera Biologics beats DBV Technologies on 11 of the 17 factors compared between the two stocks.